Skip to main content

Table 1 Patient characteristics

From: PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer

   Number Percentage
Pathological complete response (pCR) versus residual disease (RD) RD 113 80.7
  pCR 24 17.1
  Unknown 3 -
Residual cancer burden 0 24 22.6
  I 7 6.6
  II 47 44.3
  III 28 26.4
  Unknown 34 -
Estrogen receptor (ER) status ER- 62 44.3
  ER+ 78 55.7
Progesterone receptor (PR) status PR- 82 58.6
  PR+ 58 41.4
HER2 status HER2- 125 89.3
  HER2+ 15 10.7
Grade Grade 1–2 56 48.7
  Grade 3 59 51.3
  Unknown 25 -
Nodal status and T stage N0 41 29.3
  N1 62 44.3
  N2 30 21.4
  N3 7 5.0
  T1 9 6.4
  T2 71 50.7
  T3 21 15.0
  T4 39 27.9
Ethnicity Asian 3 2.1%
  Black 13 9.3%
  Hispanic 50 35.7%
  Caucasian 74 52.9%
Systemic therapy FAC/FEC 63 45.0%
  TFAC/TFEC 77 55.0%
Median age (minimum-maximum), years 51 (28–73)
  1. FAC, 5-fluoruracil, doxorubicin, and cyclophosphamide; FEC, 5-fluoruracil, epirubicin, and cyclophosphamide; TFAC, paclitaxel followed by 5-fluoruracil, doxorubicin, and cyclophosphamide; TFEC, paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide.